Recursion Pharmaceuticals (RXRX) Other Working Capital Changes (2020 - 2026)

Recursion Pharmaceuticals' Other Working Capital Changes history runs 7 years deep, the most recent figure standing at -$2.2 million for Q1 2026.

• Quarterly Other Working Capital Changes rose 76.97% year-over-year to -$2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$29.3 million (down 21.17% YoY) and the FY2025 annual result came in at -$36.8 million, down 31.15% from the prior year.
• Other Working Capital Changes was -$2.2 million for Q1 2026 at Recursion Pharmaceuticals, up from -$6.8 million in the prior quarter.
• Across five years, Other Working Capital Changes topped out at $7.6 million in Q1 2022 and bottomed at -$25.4 million in Q2 2025.
• A 5-year average of -$2.0 million and a median of $317000.0 in 2023 frame the typical range for Other Working Capital Changes.
• Peak annual rise in Other Working Capital Changes reached 5888.04% in 2022, while the deepest fall reached 5800.52% in 2022.
• Recursion Pharmaceuticals' Other Working Capital Changes stood at -$13.7 million in 2022, then surged by 43.58% to -$7.7 million in 2023, then increased by 26.59% to -$5.7 million in 2024, then fell by 19.3% to -$6.8 million in 2025, then surged by 66.73% to -$2.2 million in 2026.
• Business Quant data shows RXRX's Other Working Capital Changes at -$2.2 million in Q1 2026, -$6.8 million in Q4 2025, and -$6.6 million in Q3 2025.